Developer docs
API playgroundTry for free, no card

Search company profiles

New York Blood Center

Full company profile

uuid00086uw

Namestring
New York Blood Center
Legal namestring
New York Blood Center, Inc.
Websiteurl
nybc.org
Company typeenum
Private
Founded yearint
1964
Descriptiontext

New York Blood Center (NYBC), founded in 1964 and headquartered in Rye, NY, is one of the largest community-based, non-profit blood collection and distribution organizations in the United States, operating a multi-state network branded as New York Blood Center Enterprises (NYBCe) through wholly owned divisions in New York, New Jersey, Connecticut, Delaware, Minnesota, Nebraska, and Rhode Island. Its core products are four donation types — whole blood, double red cells, platelets, and plasma — collected primarily via automated apheresis technology, in which a cell separator isolates target components and returns the remainder to the donor. Beyond commodity blood products, NYBC runs the PreciseMatch program for ethnically matched transfusions (particularly for sickle cell patients), Comprehensive Cell Solutions for stem cell and PBSC donations via the NMDP registry, and the Lindsley F. Kimball Research Institute for research in hematology, transfusion medicine, and cellular therapies.

NYBC's go-to-market is community-led: it recruits donors through nearly 50 daily blood drives and permanent donor centers, incentivized by a suite of loyalty programs (All Seasons Lifesaver, Twice the Hero, Platelet Pact, Plasma Champion, Universal Lifesaver) and student/educational programs. Revenue is generated by selling blood products, specialty pharmaceuticals, and clinical/technical services to hospitals and healthcare providers through the BloodHub ordering platform, supplemented by clinical apheresis and Cell Saver services, research activity, and financial donations. Hospital-side distribution is anchored in the greater New York metropolitan area and supplemented by inter-center transfers through partnerships with AABB, FDNY, NYC Emergency Management, and East Coast/Midwest partner blood centers for disaster response. Hospital customer service is operated through a dedicated Customer Care Center, with named directors of Hospital Services, Immunohematology Lab, and Customer Care Center managing the enterprise-facing relationships.

Strategically, NYBC pursues scale through geographic acquisition (the NYBCe divisional model), product line extension into stem cells and cellular therapies, and deepening institutional integration via emergency preparedness coordination with city and state agencies. Notable risks include a January 2025 ransomware attack affecting 193,822 individuals and exposure to demographic and reimbursement pressures common to U.S. community blood banking. Leadership is led by Christopher D. Hillyer as President, CEO, and Chief Scientific Officer, with operational leadership including an SVP/Deputy COO of Blood & Laboratory Services and VPs and Directors across manufacturing, hospital services, donor recruitment, customer care, and the immunohematology lab.

Short descriptiontext

New York Blood Center (NYBC) is a non-profit community blood collection and distribution organization operating a multi-state NYBCe network across the Northeast and Midwest. It collects whole blood, platelets, plasma, and double red cells via apheresis and supplies hospitals through its BloodHub platform, PreciseMatch, and stem cell services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
blood collection services, blood product distribution, apheresis technology, stem cell donation, transfusion medicine research
Industry4 codes
1Transfusion Medicine & Immunohematology (Blood Bank)
CodeHLAFAMAGPrimaryYes
2Blood, Organ & Tissue Donation Organizations
CodeBPAGACAJPrimaryNo
3Blood Bank, Transfusion Medicine & Immunohematology
CodeHLAHAAAHPrimaryNo
4Cell & Tissue Banking (biobanking, cord blood/tissue)
CodeHLAAAGAEPrimaryNo
NAICS code1 code
  • Blood and Organ Banks621991
SIC code1 code
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Blood Banking & Transfusion Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Blood Products and Services to Hospitals
TypeTransaction Fee
Description

NYBC collects blood from donors and distributes blood products (red cells, platelets, plasma) to hospitals and healthcare providers. Products include whole blood and automated component collections. Also provides Clinical Apheresis and Cell Saver services to hospitals.

nybc.org
2Financial Donations
TypeGrants Donations
Description

The organization accepts financial gifts from donors to support lifesaving mission, including online donations, recurring donations, and legacy giving programs.

nybc.org
3Research and Development Services
TypeProfessional Services
Description

The Lindsley F. Kimball Research Institute conducts research in hematology, blood banking, transfusion medicine, and cellular therapies with potential worldwide humanitarian impact.

nybc.org
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
Pricing details1 tier
1Free blood donation for eligible donors
ModelOtherBilling cadencePay-as-you-go
Notes

Blood donation is free for eligible donors. NYBC provides loyalty program rewards (premium weekender bags, puffer vests, eGift cards, lunch boxes, etc.) as incentives for regular donors.

nybc.org
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1PreciseMatch
Description

A program focusing on blood needs of patients requiring specific blood types for transfusions, particularly serving diverse ethnic communities.

nybc.org
+2 more records
Core offering1 text field

New York Blood Center collects whole blood and blood components via standard venipuncture and automated apheresis from voluntary community donors at permanent centers and mobile blood drives, then processes and distributes red cells, platelets, plasma, and specialty products to hospitals and healthcare providers. It supplements blood product distribution with PreciseMatch ethnic matching, Comprehensive Cell Solutions stem cell collection, clinical apheresis and Cell Saver hospital services, and research through the Lindsley F. Kimball Research Institute.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • One pint of blood can save up to three lives
+2 more records
Product overview1 text field

New York Blood Center Enterprises (NYBCe) operates as a non-profit blood collection and distribution organization providing a comprehensive suite of blood donation services and related products. The core offerings include four types of blood donations: Whole Blood, Double Red Cells, Platelets, and Plasma, all collected via standard venipuncture or automated apheresis technology. NYBCe also offers specialized matching services through PreciseMatch for diverse ethnic backgrounds and Comprehensive Cell Solutions for stem cell donations. The organization supports healthcare providers with BloodHub (ordering), BloodBill (payments), and Lab Forms (documentation), while its Lindsley F. Kimball Research Institute drives innovation in hematology and cellular therapies. Donor engagement is maintained through Loyal Lifesavers, a multi-tiered loyalty program offering incentives for regular donations across different blood types and donation frequencies.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1AABB Disaster Response Task Force
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Facilitates interactions with government agencies and helps coordinate national or regional movement of blood supply to get inventory where it is most needed during disasters.

nybc.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Planning and coordination with hospitals in greater NYC region for emergency blood supply management.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Interagency coordination of citywide emergency planning and response for all types and scales of emergencies. Monitors Hospital Emergency Radio Network.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Facilitate and support emergency operations for public health and medical services.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Facilitate and support emergency operations and regulatory oversight for blood services.

6Partner Blood Centers (East Coast and Midwest)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Extended network includes partner blood centers ready to provide extra support in case of regional disasters and supply shortages.

nybc.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

National marrow donor program through which individuals join stem cell registry. NYBC Comprehensive Cell Solutions facilitates stem cell donations for registered matches.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pre-hospital emergency medical care coordination. Sets Mass Casualty Incidents (MCI) Notification Levels for hospitals.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

The largest single U.S. blood collector and direct competitor to NYBC, supplying about 40% of the nation's blood supply. Operates a similarly structured non-profit model with hospital distribution and mobile blood drives, making it the most directly comparable peer.

TypeDirect peer
Description

Large non-profit community blood center serving Florida, Georgia, Alabama, and the Carolinas with hospital blood supply, apheresis services, and reference lab capabilities. Closely mirrors NYBC's operating model and product mix.

TypeDirect peer
Description

Texas-based non-profit community blood center serving hospital customers with whole blood, platelets, plasma, and specialty services. Comparable in scale and operational model to NYBC's regional divisions.

TypeRegional player
Description

Regional non-profit blood center serving Southern California hospitals with comparable collection, processing, and distribution services. Functionally similar to NYBC but operating in a different geography.

TypeEmerging player
Description

National marrow donor registry and stem cell services organization that NYBC partners with for Comprehensive Cell Solutions. Operates in the overlapping cellular therapy and stem cell space, making it a strategic peer in NYBC's higher-growth vertical.

TypeDirect peer
Description

Non-profit blood center and diagnostic services organization operating across the Midwest, with apheresis, transfusion medicine, and blood product distribution. Direct functional peer to NYBC's hospital services and lab operations.

TypeRegional player
Description

Provincial non-profit blood operator in Quebec, Canada, running community-based collection and hospital distribution with research capabilities—structurally analogous to NYBC but serving a different jurisdiction.

TypeDirect peer
Description

One of the largest non-profit blood collectors in the U.S., operating across more than 30 states with a comparable model of community-based collection, hospital distribution, and specialty lab services. Directly competes with NYBC for hospital contracts.

TypeDirect peer
Description

Regional non-profit blood center serving the Pacific Northwest with hospital blood supply and transfusion medicine services. Operates with a similar community-based, non-profit model to NYBC.

TypeBroad incumbent
Description

Largest for-profit plasma collection network globally, a subsidiary of CSL Behring. While focused on source plasma rather than whole blood for hospitals, it competes for plasma donor supply and represents an alternative model for plasma-derived products that NYBC also supplies.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

New York Blood Center

Blood Banking & Transfusion Servicesnybc.org

New York Blood Center (NYBC) is a non-profit community blood collection and distribution organization operating a multi-state NYBCe network across the Northeast and Midwest. It collects whole blood, platelets, plasma, and double red cells via apheresis and supplies hospitals through its BloodHub platform, PreciseMatch, and stem cell services.

What New York Blood Center does

New York Blood Center (NYBC), founded in 1964 and headquartered in Rye, NY, is one of the largest community-based, non-profit blood collection and distribution organizations in the United States, operating a multi-state network branded as New York Blood Center Enterprises (NYBCe) through wholly owned divisions in New York, New Jersey, Connecticut, Delaware, Minnesota, Nebraska, and Rhode Island. Its core products are four donation types — whole blood, double red cells, platelets, and plasma — collected primarily via automated apheresis technology, in which a cell separator isolates target components and returns the remainder to the donor. Beyond commodity blood products, NYBC runs the PreciseMatch program for ethnically matched transfusions (particularly for sickle cell patients), Comprehensive Cell Solutions for stem cell and PBSC donations via the NMDP registry, and the Lindsley F. Kimball Research Institute for research in hematology, transfusion medicine, and cellular therapies.

NYBC's go-to-market is community-led: it recruits donors through nearly 50 daily blood drives and permanent donor centers, incentivized by a suite of loyalty programs (All Seasons Lifesaver, Twice the Hero, Platelet Pact, Plasma Champion, Universal Lifesaver) and student/educational programs. Revenue is generated by selling blood products, specialty pharmaceuticals, and clinical/technical services to hospitals and healthcare providers through the BloodHub ordering platform, supplemented by clinical apheresis and Cell Saver services, research activity, and financial donations. Hospital-side distribution is anchored in the greater New York metropolitan area and supplemented by inter-center transfers through partnerships with AABB, FDNY, NYC Emergency Management, and East Coast/Midwest partner blood centers for disaster response. Hospital customer service is operated through a dedicated Customer Care Center, with named directors of Hospital Services, Immunohematology Lab, and Customer Care Center managing the enterprise-facing relationships.

Strategically, NYBC pursues scale through geographic acquisition (the NYBCe divisional model), product line extension into stem cells and cellular therapies, and deepening institutional integration via emergency preparedness coordination with city and state agencies. Notable risks include a January 2025 ransomware attack affecting 193,822 individuals and exposure to demographic and reimbursement pressures common to U.S. community blood banking. Leadership is led by Christopher D. Hillyer as President, CEO, and Chief Scientific Officer, with operational leadership including an SVP/Deputy COO of Blood & Laboratory Services and VPs and Directors across manufacturing, hospital services, donor recruitment, customer care, and the immunohematology lab.

New York Blood Center firmographics

Firmographics
Name
New York Blood Center
Legal name
New York Blood Center, Inc.
Website
https://nybc.org
Company type
Private
Founded year
1964
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
New York Blood Center (NYBC) is a non-profit community blood collection and distribution organization operating a multi-state NYBCe network across the Northeast and Midwest. It collects whole blood, platelets, plasma, and double red cells via apheresis and supplies hospitals through its BloodHub platform, PreciseMatch, and stem cell services.
Ownership category
akta.pro rank

New York Blood Center industry classification

Industry
Product category
Blood Banking & Transfusion Services
NAICS
Blood and Organ Banks (621991)
SIC
Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro primary industry
Transfusion Medicine & Immunohematology (Blood Bank) (HLAFAMAG)
akta.pro secondary industries
Blood, Organ & Tissue Donation Organizations (BPAGACAJ), Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH), Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

Keywords

  • Blood collection services
  • Blood product distribution
  • Apheresis technology
  • Stem cell donation
  • Transfusion medicine research

Where New York Blood Center is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

New York Blood Center business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Blood Products and Services to Hospitals: NYBC collects blood from donors and distributes blood products (red cells, platelets, plasma) to hospitals and healthcare providers. Products include whole blood and automated component collections. Also provides Clinical Apheresis and Cell Saver services to hospitals.
  2. Financial Donations: The organization accepts financial gifts from donors to support lifesaving mission, including online donations, recurring donations, and legacy giving programs.
  3. Research and Development Services: The Lindsley F. Kimball Research Institute conducts research in hematology, blood banking, transfusion medicine, and cellular therapies with potential worldwide humanitarian impact.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goFree blood donation for eligible donors

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

New York Blood Center product offering

Product offering

Core offering

New York Blood Center collects whole blood and blood components via standard venipuncture and automated apheresis from voluntary community donors at permanent centers and mobile blood drives, then processes and distributes red cells, platelets, plasma, and specialty products to hospitals and healthcare providers. It supplements blood product distribution with PreciseMatch ethnic matching, Comprehensive Cell Solutions stem cell collection, clinical apheresis and Cell Saver hospital services, and research through the Lindsley F. Kimball Research Institute.

Product overview

New York Blood Center Enterprises (NYBCe) operates as a non-profit blood collection and distribution organization providing a comprehensive suite of blood donation services and related products. The core offerings include four types of blood donations: Whole Blood, Double Red Cells, Platelets, and Plasma, all collected via standard venipuncture or automated apheresis technology. NYBCe also offers specialized matching services through PreciseMatch for diverse ethnic backgrounds and Comprehensive Cell Solutions for stem cell donations. The organization supports healthcare providers with BloodHub (ordering), BloodBill (payments), and Lab Forms (documentation), while its Lindsley F. Kimball Research Institute drives innovation in hematology and cellular therapies. Donor engagement is maintained through Loyal Lifesavers, a multi-tiered loyalty program offering incentives for regular donations across different blood types and donation frequencies.

Differentiator

Problem solved

Functional benefit

Brands

  • PreciseMatch: A program focusing on blood needs of patients requiring specific blood types for transfusions, particularly serving diverse ethnic communities.
  • Bloodstock
  • Little Doctors Program

Quantifiable outcome

  • One pint of blood can save up to three lives
  • +2 more outcomes

Companies that use New York Blood Center

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

New York Blood Center technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

New York Blood Center partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core.

  • AABB Disaster Response Task ForcecoreStrategic or Co-development PartnerFacilitates interactions with government agencies and helps coordinate national or regional movement of blood supply to get inventory where it is most needed during disasters.
  • GNYHA Emergency Preparedness Coordinating CouncilcoreStrategic or Co-development PartnerPlanning and coordination with hospitals in greater NYC region for emergency blood supply management.
  • NYC Emergency ManagementcoreStrategic or Co-development PartnerInteragency coordination of citywide emergency planning and response for all types and scales of emergencies. Monitors Hospital Emergency Radio Network.
  • NYC Department of Health and Mental HygienecoreStrategic or Co-development PartnerFacilitate and support emergency operations for public health and medical services.
  • State Departments of Health (NY, NJ, CT, PA)coreStrategic or Co-development PartnerFacilitate and support emergency operations and regulatory oversight for blood services.
  • Partner Blood Centers (East Coast and Midwest)coreStrategic or Co-development PartnerExtended network includes partner blood centers ready to provide extra support in case of regional disasters and supply shortages.
  • NMDP (formerly Be The Match)coreStrategic or Co-development PartnerNational marrow donor program through which individuals join stem cell registry. NYBC Comprehensive Cell Solutions facilitates stem cell donations for registered matches.
  • FDNYcoreStrategic or Co-development PartnerPre-hospital emergency medical care coordination. Sets Mass Casualty Incidents (MCI) Notification Levels for hospitals.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

New York Blood Center competitors and assessment

Company assessment

Direct peers

  • American Red Cross: The largest single U.S. blood collector and direct competitor to NYBC, supplying about 40% of the nation's blood supply. Operates a similarly structured non-profit model with hospital distribution and mobile blood drives, making it the most directly comparable peer.
  • OneBlood: Large non-profit community blood center serving Florida, Georgia, Alabama, and the Carolinas with hospital blood supply, apheresis services, and reference lab capabilities. Closely mirrors NYBC's operating model and product mix.
  • Carter BloodCare: Texas-based non-profit community blood center serving hospital customers with whole blood, platelets, plasma, and specialty services. Comparable in scale and operational model to NYBC's regional divisions.
  • Versiti: Non-profit blood center and diagnostic services organization operating across the Midwest, with apheresis, transfusion medicine, and blood product distribution. Direct functional peer to NYBC's hospital services and lab operations.
  • Vitalant: One of the largest non-profit blood collectors in the U.S., operating across more than 30 states with a comparable model of community-based collection, hospital distribution, and specialty lab services. Directly competes with NYBC for hospital contracts.
  • Bloodworks Northwest: Regional non-profit blood center serving the Pacific Northwest with hospital blood supply and transfusion medicine services. Operates with a similar community-based, non-profit model to NYBC.

Regional players

  • San Diego Blood Bank: Regional non-profit blood center serving Southern California hospitals with comparable collection, processing, and distribution services. Functionally similar to NYBC but operating in a different geography.
  • Héma-Québec: Provincial non-profit blood operator in Quebec, Canada, running community-based collection and hospital distribution with research capabilities—structurally analogous to NYBC but serving a different jurisdiction.

Emerging players

  • NMDP (formerly Be The Match): National marrow donor registry and stem cell services organization that NYBC partners with for Comprehensive Cell Solutions. Operates in the overlapping cellular therapy and stem cell space, making it a strategic peer in NYBC's higher-growth vertical.

Broad incumbents

  • CSL Plasma: Largest for-profit plasma collection network globally, a subsidiary of CSL Behring. While focused on source plasma rather than whole blood for hospitals, it competes for plasma donor supply and represents an alternative model for plasma-derived products that NYBC also supplies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

New York Blood Center social profiles

Digital presence

New York Blood Center financial estimates

Financial estimate

Revenue estimate

Valuation estimate

New York Blood Center leadership team

Management profile

Number of profiles

Profiles10 records

New York Blood Center subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

New York Blood Center funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

New York Blood Center M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about New York Blood Center

What does New York Blood Center do?

New York Blood Center collects whole blood and blood components via standard venipuncture and automated apheresis from voluntary community donors at permanent centers and mobile blood drives, then processes and distributes red cells, platelets, plasma, and specialty products to hospitals and healthcare providers. It supplements blood product distribution with PreciseMatch ethnic matching, Comprehensive Cell Solutions stem cell collection, clinical apheresis and Cell Saver hospital services, and research through the Lindsley F. Kimball Research Institute.

Is New York Blood Center a public or private company?

New York Blood Center is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was New York Blood Center founded?

New York Blood Center was founded in 1964. It employs 1,001 to 5,000 people.

Where is New York Blood Center based?

New York Blood Center is headquartered in New York, United States, in the North America region.

How does New York Blood Center make money?

Three revenue lines are on record. Blood Products and Services to Hospitals are the primary driver. The others are financial Donations and research and Development Services.

Who are New York Blood Center's main competitors?

Direct peers on record are American Red Cross, OneBlood, Carter BloodCare, Versiti, Vitalant and Bloodworks Northwest. Regional players are San Diego Blood Bank and Héma-Québec. NMDP (formerly Be The Match) is listed as an emerging player. CSL Plasma is listed as a broad incumbent.

Does New York Blood Center have an API?

No public API is recorded for New York Blood Center.

What industry is New York Blood Center in?

New York Blood Center's product category is Blood Banking & Transfusion Services. Its primary akta.pro industry code is HLAFAMAG, Transfusion Medicine & Immunohematology (Blood Bank), with a secondary code of BPAGACAJ, Blood, Organ & Tissue Donation Organizations. Its NAICS code is 621991 and its SIC code is 5047.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PRESSBEENEW YORK BLOOD CENTER ENTERPRISES APPOINTS MEGHAN DELANEY, DO, MPH, AS NEXT PRESIDENT & CHIEF EXECUTIVE OFFICER ...Middle EastThe Board of Trustees of New York Blood Center Enterprises appointed Meghan Delaney, DO, MPH, as its next president and chief executive officer. Current president and CEO Christopher D. Hillyer, MD, will serve as special advisor to the board.YahooUrgent call for blood donations following Nor’easterThe New York Blood Center and New Jersey Blood Services lost an estimated 1,000 donations due to last weekend's Nor'easter, which canceled drives and kept people indoors. The region is about 2,700 donations short of meeting current demand, with urgent calls for O+ and O-negative blood types.YahooNor’easter causes blood donation losses across NY, NJA nor'easter canceled blood drives and left about 1,000 donors unable to travel, according to the New York Blood Center. September is forecast to be the most challenging month for collections, with nearly 2,700 fewer donations than needed. The center urges eligible donors to make appointments this week to recover the lost supply.Crain's New York BusinessLong Island City Blood Center site sells for $95M ahead of planned 495-unit projectA former New York Blood Center site in Long Island City sold for $95 million and is set to be redeveloped into a mixed-use project with nearly 500 residential units. The sale occurs ahead of the planned 495-unit development.GlobeNewswireNew York Blood Center Enterprises and Biohub Launch Collaboration to Advance Cord Blood–Derived Stem Cell PlatformsNew York Blood Center Enterprises and Biohub announced a collaboration to develop induced pluripotent stem cells from cord blood immune cells. The effort uses NYBCe's 30,000+ cord blood units and Biohub's reprogramming expertise to create standardized iPSC lines for regenerative medicine and cell therapy.The Times of IndiaJust 1 day left to claim up to $2,500 from the New York Blood Center data breach settlement — check if you qualifyNearly 194,000 donors have until February 11, 2026 to file claims in a $500,000 settlement fund established by the New York Blood Center following a 2025 data breach that exposed Social Security numbers and medical files. Eligible claimants can receive up to $2,500 for documented identity theft losses or a flat cash payment without documentation. The settlement resolves claims stemming from the cybersecurity incident that compromised sensitive personal information of approximately 193,814 Americans.GoogleMX2025013576A - Compositions targeting hbg1 and hbg2 and methods of use thereof - Google PatentsThe article lists various patents and patent applications related to biomedical and genetic technologies, such as targeted compositions for treating hemoglobinopathies, gene editing tools, and delivery systems for proteins and nucleic acids. Several entities, including New York Blood Center, Inc., Vindico NanoBio Technology Inc., and Poseida Therapeutics, Inc., are involved in the development of these innovations. The developments span multiple jurisdictions, including the US, Europe, and Japan.GlobeNewswireNew York Blood Center Enterprises Celebrates the Expansion of Cell & Gene Therapy GMP Manufacturing Capabilities at the Grand Opening of Louisville, Kentucky SiteComprehensive Cell Solutions, a unit of New York Blood Center Enterprises, opened its GMP cell and gene therapy manufacturing facility in Louisville, Kentucky, on the University of Louisville campus. The 20,000-square-foot site includes two ISO 7 cleanrooms and end-to-end capabilities, expanding CCS's national CDMO footprint.NybceNew York Blood Center Enterprises Makes Investment to Advance Next-Generation Red Blood Cell ResearchNew York Blood Center Enterprises (NYBCe) announced an investment through its venture fund, NYBC Ventures, into Functional Fluidics to advance research in sickle cell disease and transfusion medicine. Functional Fluidics will utilize these funds to expand its diagnostic services to Africa and develop next-generation red blood cell health assays aimed at improving patient outcomes globally.BioSpaceAronora Secures Investment From New York Blood CenterAronora, Inc. has closed an investment from NYBC Ventures, the venture fund established by the New York Blood Center. The funding will support team expansion, manufacturing, and regulatory activities for Aronora's lead drug candidates E-WE thrombin (AB002) and Gruticibart (AB023) as they prepare for late-stage clinical development. Both investigational products have completed phase 2a trials with compelling data targeting blood clot treatment without increasing bleeding risks.